06/18/2009 - Rhode Island, 35 other states, the District of Columbia and the federal government have reached an agreement with Eli Lilly and Co. to settle allegations that that drugmaker engaged in a six-year “off-label” marketing campaign that improperly promoted the anti-psychotic drug Zyprexa. More>>>

06/18/2009 - Kentucky Attorney General Jack Conway has settled with drug maker Eli Lilly and Co. over allegations of improper marketing of its Zyprexa antipsychotic drug. More>>>

06/18/2009 - Pharmaceutical company Eli Lilly was forced to pay more than $1.7 million to Nebraska on allegations that it improperly marketed an antipsychotic drug. More>>>

06/18/2009 - Colorado has now received its $2.6 million share of a multistate settlement with Eli Lilly and Co. over allegations that the drugmaker improperly promoted the anti-psychotic drug, Zyprexa, state Attorney General John Suthers announced Friday. More>>>

06/17/2009 - Bloomberg reports a U.S. District Court Judge has allowed law suits to move forward against Eli Lilly, the drug company is accused of selling and encouraging physicians to prescribe the drug Zyprexa for uses never proven or approved by the FDA. More>>>

06/16/2009 - Eli Lilly & Co.’s atypical antipsychotic medication, Zyprexa, was not only marketed to doctors for an unapproved, off-label use — the treatment of dementia in elderly patients — but it was done despite Lilly’s access and knowledge of at least seven studies that showed the drug was apparently ineffective for the treatment of dementia. More>>>

06/16/2009 - A unit of CVS Caremark Corp. used its access to doctors to market Eli Lilly & Co.'s Zyprexa antipsychotic while it was under contract to bargain with the drug maker on behalf of health insurers, internal Lilly files disclosed in a multibillion-dollar lawsuit by insurers show. More>>>

More News ::

FDA Medication Guide ::

Zyprexa ( Zyprexa Olanzapine ) is an anti-psychotic medication that was approved in 1996 by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia. It is often prescribed for other problems such as anxiety and depression. Zyprexa is a member of a class of drugs commonly referred to as "second generation anti-psychotics" ("SGA's") or "atypical anti-psychotics." When Zyprexa ( Olanzapine ) was approved in 1996, there were 2 other such SGA medications already available on the market. Consequently, Zyprexa is considered a "me-too" drug, joining a class of existing medications prescribed for the treatment of common disorders.

The SGA's were developed as an alternative to the so-called "first generation anti-psychotics" ("FGA's"). The SGA's were designed to be more effective in the treatment of anti-psychotic disorders with fewer of the side effects generally associated with the use of FGA's.

Of six SGA's currently available, Zyprexa is the most commonly prescribed. The generic name of Zyprexa is olanzapine. Zyprexa has been prescribed to more than 14 million people in 84 countries since its approval in 1996.


In September 2003, the FDA ordered Eli Lilly to revise Zyprexa's label by adding a side effects warning that "hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical anti-psychotics." Among the more serious outcomes resulting from hyperglycemic abnormalities are diabetes, diabetic ketoacidosis, diabetic coma and, in some cases death. * Zyprexa weight gain is also a commonly reported side effect.

- Diabetes
- Diabetic Ketoacidosis
- Diabetic Coma
- Hyperosmolar Coma
- Hyperglycemia

If you are currently taking Zyprexa and have concerns about its safetly, you should consult with your doctor regarding your treatment options. Under no circumstances should you discontinue taking any medication, including Zyprexa, without first consulting with your doctor. For Zyprexa legal information contact the Zyprexa Attorneys of Ennis & Ennis, P.A. by filling out our free Zyrpexa case evaluation form or by calling the toll-free number listed below.